Published on 3 May 2022 on Zacks via Yahoo Finance
MacroGenics (MGNX) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.90 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -28.57%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.83 per share when it actually produced a loss of $0.95, delivering a surprise of -14.46%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.